Bill journey · stage 2 of 5
Under committee review
What it doesSummary passed house (Sep 29, 2020)
Creating Hope Reauthorization Act
This bill reauthorizes a Food and Drug Administration (FDA) program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)
Specifically, the bill reauthorizes the program through FY2024, but the FDA may award a voucher afterwards in certain instances.
What just happenedSep 30, 2020
Received in the Senate.
Who’s behind it
Received in the Senate.
The title of the measure was amended. Agreed to without objection.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5023)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
DEBATE - The House proceeded with forty minutes of debate on H.R. 4439.
Considered under suspension of the rules. (consideration: CR H5023-5025)
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 451.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-551.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-551.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Creating Hope Reauthorization Act
This bill reauthorizes a Food and Drug Administration (FDA) program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)
Specifically, the bill reauthorizes the program through FY2024, but the FDA may award a voucher afterwards in certain instances.
Creating Hope Reauthorization Act
This bill permanently reauthorizes a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)